BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...and hypertension have been around for decades, Quantum Genomics Corp....
BioCentury | Jan 12, 2019
Finance

We all fall down

...median of 29% with a total loss of $26.5 billion. One of its smallest members, Quantum Genomics Corp....
...Therapeutics Inc. (NASDAQ:NKTR), San Francisco, Calif. Pacific Biosciences of California Inc. (NASDAQ:PACB), Menlo Park, Calif. Quantum Genomics Corp....
...Research & Analytics Bausch Health Companies Inc. DBV Technologies S.A. Exelixis Inc. Illumina Inc. Nektar Therapeutics Inc. Pacific Biosciences of California Inc. Quantum Genomics Corp. Sage...
BioCentury | Oct 17, 2016
Clinical News

QGC001: Phase IIa data

...1H17, Quantum plans to submit an IND to FDA for a U.S. Phase II trial. Quantum Genomics Corp....
BioCentury | Jul 18, 2016
Clinical News

QGC101: Phase IIa started

...twice daily for 28 days in about 75 CHF patients with altered cardiac ejection fraction. Quantum Genomics Corp....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...Inc. (NASDAQ:CTRV) 3/30/16 $7.0 $45.8 $39.0 -15% BioPharmX Corp. (NYSE-M:BPMX) 3/29/16 $4.3 $34.6 $31.4 -9% Quantum Genomics Corp....
BioCentury | Mar 28, 2016
Financial News

Quantum Genomics completes follow-on

Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Business: Cardiovascular Date completed: 2016-03-24 Type: Follow-on Raised: EUR3 million ($3.4 million) Shares: 506,329 Price: EUR6 Shares after offering: 8.3 million Underwriter: Invest Securities Note: Investors also received 30-month...
BioCentury | Mar 28, 2016
Financial News

Quantum Genomics completes private placement of common stock and warrants

Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Business: Cardiovascular Date completed: 2016-03-17 Type: Private placement of common stock and warrants Raised: EUR5.5 million ($6.2 million) Shares: 923,644 Price: EUR6 Shares after offering: 7.9 million Placement agent:...
BioCentury | Oct 19, 2015
Clinical News

QGC001: Phase IIa ongoing

...last month, the company said the trial had enrolled >50% of the planned 30 patients. Quantum Genomics Corp....
BioCentury | Aug 17, 2015
Company News

Quantum Genomics, University of Ottawa, Institut National de la Sante et de la Recherche Medicale deal

...did not respond to inquiries. CIRB is located at the College de France (Paris, France). Quantum Genomics Corp....
BioCentury | Feb 23, 2015
Financial News

Quantum Genomics Corp completes private placement

Quantum Genomics Corp . (Euronext:ALQGC), Massy, France Business: Cardiovascular Date completed: 2015-02-17 Type: Private placement Raised: EUR11.2 million ($12.8 million) Shares: 1.8 million Price: EUR6.30 Shares after offering: 6.6 million Investors: Institutional investors; existing investors; Tethys...
Items per page:
1 - 10 of 26
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...and hypertension have been around for decades, Quantum Genomics Corp....
BioCentury | Jan 12, 2019
Finance

We all fall down

...median of 29% with a total loss of $26.5 billion. One of its smallest members, Quantum Genomics Corp....
...Therapeutics Inc. (NASDAQ:NKTR), San Francisco, Calif. Pacific Biosciences of California Inc. (NASDAQ:PACB), Menlo Park, Calif. Quantum Genomics Corp....
...Research & Analytics Bausch Health Companies Inc. DBV Technologies S.A. Exelixis Inc. Illumina Inc. Nektar Therapeutics Inc. Pacific Biosciences of California Inc. Quantum Genomics Corp. Sage...
BioCentury | Oct 17, 2016
Clinical News

QGC001: Phase IIa data

...1H17, Quantum plans to submit an IND to FDA for a U.S. Phase II trial. Quantum Genomics Corp....
BioCentury | Jul 18, 2016
Clinical News

QGC101: Phase IIa started

...twice daily for 28 days in about 75 CHF patients with altered cardiac ejection fraction. Quantum Genomics Corp....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...Inc. (NASDAQ:CTRV) 3/30/16 $7.0 $45.8 $39.0 -15% BioPharmX Corp. (NYSE-M:BPMX) 3/29/16 $4.3 $34.6 $31.4 -9% Quantum Genomics Corp....
BioCentury | Mar 28, 2016
Financial News

Quantum Genomics completes follow-on

Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Business: Cardiovascular Date completed: 2016-03-24 Type: Follow-on Raised: EUR3 million ($3.4 million) Shares: 506,329 Price: EUR6 Shares after offering: 8.3 million Underwriter: Invest Securities Note: Investors also received 30-month...
BioCentury | Mar 28, 2016
Financial News

Quantum Genomics completes private placement of common stock and warrants

Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Business: Cardiovascular Date completed: 2016-03-17 Type: Private placement of common stock and warrants Raised: EUR5.5 million ($6.2 million) Shares: 923,644 Price: EUR6 Shares after offering: 7.9 million Placement agent:...
BioCentury | Oct 19, 2015
Clinical News

QGC001: Phase IIa ongoing

...last month, the company said the trial had enrolled >50% of the planned 30 patients. Quantum Genomics Corp....
BioCentury | Aug 17, 2015
Company News

Quantum Genomics, University of Ottawa, Institut National de la Sante et de la Recherche Medicale deal

...did not respond to inquiries. CIRB is located at the College de France (Paris, France). Quantum Genomics Corp....
BioCentury | Feb 23, 2015
Financial News

Quantum Genomics Corp completes private placement

Quantum Genomics Corp . (Euronext:ALQGC), Massy, France Business: Cardiovascular Date completed: 2015-02-17 Type: Private placement Raised: EUR11.2 million ($12.8 million) Shares: 1.8 million Price: EUR6.30 Shares after offering: 6.6 million Investors: Institutional investors; existing investors; Tethys...
Items per page:
1 - 10 of 26